Quality Systems – Page 51

Formulation robustness underestimated during early development – regulatory scrutiny implications

Understanding Formulation Robustness Underestimation in Early Development and Its Regulatory Implications In the pharmaceutical industry, the robustness of a formulation during early development is crucial for ensuring product quality, consistency,…

Method development instability during transfer to manufacturing – data package improvements for filing

Addressing Method Development Instability When Transitioning to Manufacturing In the competitive landscape of pharmaceutical development, the stability of analytical methods during the transfer to manufacturing can pose significant challenges. Inconsistent…

Tech transfer readiness gaps during early development – downstream GMP risk and prevention

Addressing Readiness Gaps in Tech Transfer to Mitigate GMP Risks In the realm of pharmaceutical manufacturing, tech transfer during early development phases can present significant challenges. Often overlooked, these readiness…

Scale-up risk not identified during pilot scale – how to ensure smooth tech transfer

Addressing Unidentified Scale-Up Risks During Pilot Scale in Pharmaceutical Development In the pharmaceutical industry, the transition from pilot scale to full production can be fraught with risks that may not…

Method transfer mismatch in stability testing – how to distinguish lab error vs true failure

Identifying and Addressing Method Transfer Mismatch in Stability Testing In a pharmaceutical manufacturing environment, detecting a method transfer mismatch in stability testing can be a significant concern. Such discrepancies not…

Tech transfer readiness gaps during transfer to manufacturing – regulatory scrutiny implications

Understanding Tech Transfer Readiness Gaps and Their Regulatory Implications in Manufacturing In the life sciences sector, successful tech transfer to manufacturing is critical for maintaining compliance with Good Manufacturing Practices…

OOS investigation lacks root cause during data review and approval – CAPA package with objective evidence

OOS Investigations: Navigating Root Cause Challenges in Data Review and Approval In the pharmaceutical manufacturing environment, Out-of-Specification (OOS) results pose significant compliance challenges. A scenario often encountered is the lack…

Excipient variability impact during comparability assessment – regulatory scrutiny implications

Understanding the Impact of Excipient Variability in Comparability Assessments and Its Regulatory Implications The pharmaceutical industry faces a myriad of challenges when it comes to maintaining compliance and ensuring product…

Unplanned process deviation during night shift operations – batch disposition decision tree for QA alignment

Addressing Unplanned Process Deviations During Night Shift Operations in Pharma Manufacturing In the highly regulated field of pharmaceutical manufacturing, unplanned process deviations can occur unexpectedly, particularly during night shift operations…

Tag: Quality Systems